Wire · opportunities
FDA Grants Fast Track Designation to Pan-RAS Molecular Glue ERAS-0015 for Metastatic ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 August 2026 · Fusion42 review
The FDA granted fast track designation to ERAS-0015, an oral pan-RAS molecular glue, for treating metastatic pancreatic adenocarcinoma, based on promising phase 1 data. Erasca plans phase 3 and additional pivotal trials to further evaluate ERAS-0015 in pancreatic and lung cancers, with further clinical data expected in early 2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
The FDA's fast track for ERAS-0015 opens a regulatory shortcut that speeds development for pancreatic cancer therapies. You developing mutant RAS inhibitors gain a clearer path and should prepare for accelerated clinical and regulatory engagement.
◆ Coverage
2 sources · 24 Aug 2026
◆ Related on Wire
◆ Topics